Compare ROG & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROG | IRON |
|---|---|---|
| Founded | 1832 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 1994 | 2020 |
| Metric | ROG | IRON |
|---|---|---|
| Price | $124.74 | $82.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $133.00 | $103.18 |
| AVG Volume (30 Days) | 205.8K | ★ 317.2K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $879,091,000.00 | N/A |
| Revenue This Year | $7.64 | N/A |
| Revenue Next Year | $6.09 | $283.52 |
| P/E Ratio | $491.36 | ★ N/A |
| Revenue Growth | ★ 7.07 | N/A |
| 52 Week Low | $75.14 | $40.00 |
| 52 Week High | $169.00 | $99.50 |
| Indicator | ROG | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 62.03 |
| Support Level | $102.05 | $70.73 |
| Resistance Level | $145.22 | $82.74 |
| Average True Range (ATR) | 4.33 | 2.77 |
| MACD | -0.86 | 0.06 |
| Stochastic Oscillator | 16.22 | 86.27 |
Rogers Corp designs develop and manufactures engineered materials and components for sale to original equipment manufacturers and component suppliers. The firm operates in three business segments: Advanced Electronics Solutions, which manufactures circuit materials for applications in communications infrastructure, automotive, and consumer electronics markets; elastomeric material solutions, which provide cushioning, sealing, and impact protection in automotive, transportation, and construction applications; and Other, which consists of elastomer components for applications in the general industrial market, as well as elastomer floats for level sensing in fuel tanks, motors, and storage tanks applications in the general industrial and automotive markets.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.